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Abstract
Aims/hypothesis We investigated whether atorvastatin 10 mg
daily lowered C-reactive protein (CRP) and whether the ef-
fects of atorvastatin on cardiovascular disease (CVD) varied
by achieved levels of CRP and LDL-cholesterol.
Methods CRP levels were measured at baseline and 1 year
after randomisation to atorvastatin in 2,322 patients with type
2 diabetes (40–75 years, 69% males) in a secondary analysis
of the Collaborative Atorvastatin Diabetes Study, a
randomised placebo-controlled trial. We used Cox regression
models to test the effects on subsequent CVD events (n=147)
of CRP and LDL-cholesterol lowering at 1 year.
Results After 1 year, the atorvastatin arm showed a net CRP
lowering of 32% (95% CI −40%, −22%) compared with
placebo. The CRP response was highly variable, with 45% of
those on atorvastatin having no decrease in CRP (median [inter-
quartile range, IQR] per cent change −9.8% [−57%, 115%]).
The LDL-cholesterol response was less variable, with a median
(IQR) within-person per cent change of −41% (−51%, −31%).
Baseline CRP did not predict CVD over 3.8 years of follow-up
(HRper SD log 0.89 [95% CI 0.75, 1.06]), whereas baseline LDL-
cholesterol predicted CVD (HRper SD 1.21 [95%CI 1.02, 1.44]),
as did on-treatment LDL-cholesterol. There was no significant
difference in the reduction in CVD by atorvastatin, with above
median (HR 0.57) or belowmedian (HR0.52) change in CRP or
change in LDL-cholesterol (HR 0.61 vs 0.50).
Conclusions/interpretation CRP was not a strong predictor of
CVD. Statin efficacy did not vary with achieved CRP despite
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considerable variability in CRP response. The use of CRP as
an indicator of efficacy of statin therapy on CVD risk in pa-
tients with type 2 diabetes is not supported by these data.
Trial registration NCT00327418
Keywords Atorvastatin . Cardiovascular disease . CARDS .
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Abbreviations
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial
CARDS Collaborative Atorvastatin Diabetes Study
CRP C-reactive protein
CVD Cardiovascular disease
IQR Interquartile range
JUPITER Justification for the Use of Statins in Primary
Prevention: an Intervention Trial Evaluating
Rosuvastatin
Introduction
Statins have been shown to be beneficial in reducing cardio-
vascular disease (CVD) in patients with type 2 diabetes [1, 2],
but it remains unclear whether these effects can be explained
by their lipid-lowering effects only. Several studies show that
statins reduce the inflammatory biomarker high-sensitivity
C-reactive protein (CRP), an effect that is thought to be
independent of change in LDL-cholesterol, based on
low correlations (<0.1) between statin change in CRP and
LDL-cholesterol [3–6].
Several studies have also suggested that part of the effect of
statins on CVD is mediated through lowering of CRP con-
centrations [6–10]. JUPITER, The Justification for the
Use of Statins in Primary Prevention: an Intervention
Trial Evaluating Rosuvastatin, demonstrated, in 15,548
study participants with elevated CRP levels (≥2 mg/l),
greater relative reductions in CVD in those achieving target
post-treatment LDL-cholesterol and CRP levels, compared
with an LDL-cholesterol target only, with rosuvastatin
20 mg/day [6]. These data have been used both as supportive
evidence for developing specific CRP-reducing therapies for
preventing CVD and also to suggest the clinical utility of CRP
levels as targets for statin therapy alongside LDL-cholesterol
levels. However, other statin trials, such as the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT) Lipid-
Lowering Arm have not supported these findings [11, 12].
The most recent ASCOT analyses showed that CVD risk re-
ductions with statin therapy did not vary by achieved CRP
levels in hypertensive patients treated with atorvastatin for
6 months [12]. In the Heart Protection Study, baseline CRP
levels did not predict statin response on CVD events in over
20,000 men and women treated with simvastatin or placebo
during 5 years [13].
It is controversial whether CRP should be used as a target
biomarker to assess the effects of statin treatment [14]. Most
of these previous studies [6, 12, 13] primarily evaluated pa-
tients without type 2 diabetes. Baseline and not on-treatment
CRP levels were analysed in the Heart Protection Study [13];
JUPITER included only people with initial CRP levels >2 mg/l
and thus was unable to investigate lower CRP levels. As there
is evidence that CRP levels are higher in patients with type 2
diabetes, we investigated whether there was evidence to sup-
port the clinical relevance of changingCRP levels during 1 year
of follow-up with low-dose atorvastatin in a diabetes-specific
trial without restrictions on the initial CRP level.
Specifically, we investigated whether CRP predicted CVD
events, whether atorvastatin 10 mg daily lowered CRP and
whether the effects of atorvastatin on CVD differed by achieved
post-treatment CRP levels in a large sample of patients with
type 2 diabetes from the Collaborative Atorvastatin Diabetes
Study (CARDS). To directly compare results for CRP, all asso-
ciations were also investigated for LDL-cholesterol.
Methods
We performed a secondary analysis of CARDS, a multicentre,
randomised, placebo-controlled trial that tested whether ator-
vastatin 10 mg daily reduced the incidence of cardiovascular
outcomes in patients with type 2 diabetes [1, 15, 16]. Patients
were randomised between November 1997 and June 2001.
The study was conducted in accordance with the Declaration
of Helsinki and the guidelines on good clinical practice. Each
centre obtained local research ethics committee approval
following approval from the Multicentre Research Ethics
Committee. All patients gave fully informed written consent.
Study population Details of the trial have previously been
published [1, 15, 16]. In brief, the total CARDS study popu-
lation consisted of 2,838 type 2 diabetic men and women,
aged 40–75 years, without prior history of myocardial infarc-
tion, unstable angina, coronary vascular surgery, cerebrovas-
cular accident or severe peripheral vascular disease (defined as
warranting surgery). All patients were required to have serum
LDL-cholesterol ≤4.14 mmol/l (160 mg/dl) and serum triacyl-
glycerol ≤6.78 mmol/l (600 mg/dl) at inclusion. Type 2 diabetes
was defined using 1985World Health Organization criteria [17].
Laboratory measurements Blood samples were collected
after patients had fasted for at least 12 h. All biochemical
and haematological measurements were made by a central
laboratory at the Manchester Royal Infirmary, Manchester,
UK. Of the total 2,838 participants, 374 were excluded due
to lack of CRP data, leaving 2,464 participants for analysis. Of
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these 2,464 participants, 142 did not have a 1 year CRP
measurement, leaving 2,322 participants with both baseline
and 1 year CRP measurements. All baseline CRP and
LDL-cholesterol samples were taken at randomisation
before the study drug was given. Follow-up CRP measure-
ments were all taken at the same time on stored samples using
a defined visit schedule (366 days post randomisation), with
the timing being allowed to vary within an agreed window of
between 276 and 457 days post randomisation.
CRP concentrations were assayed in EDTA plasma sam-
ples by immunonephelometric methods using a BN II
analyser (Siemens-Dade-Behring, Marburg, Germany). Labo-
ratory reference values were 0–28.6 nmol/l (3 mg/l) for CRP.
Intra- and interassay coefficients of variation were <8% for
CRP. Lipaemic samples were diluted twofold with saline
before centrifugation in 1 ml Eppendorf Tubes using an
MSE Microfuge (London, UK) for 3 min at 14,000g. CRP
was assayed in the infranatant.
Serum cholesterol and triacylglycerol concentrations
were assessed by an automated enzymatic method.
LDL-cholesterol was calculated using the Friedewald
formula as described previously [1].
Study outcomes Fatal and non-fatal major CVD events in-
cluded acute coronary heart disease (myocardial infarction,
including silent infarction), unstable angina, acute coronary
heart disease death, resuscitated cardiac arrest, coronary
revascularisation procedures (coronary artery bypass
graft surgery, percutaneous transluminal coronary angio-
plasty) or stroke as previously described [1, 15]. Any
CVD event included major CVD, other cardiac death,
hospitalised angina, non-fatal transient ischaemic attack, other
non-fatal CVD or peripheral vascular disease events. An
independent endpoint committee reviewed all cardiovascular
events and deaths and classified them according to criteria
specified in a detailed endpoint protocol. In addition to clinical
events, annual ECGs wereMinnesota-coded by two observers
blinded to each other’s coding for the detection of silent
myocardial infarction, and changes were confirmed as
significant by a panel of cardiologists.
Statistical analysis To examine the effect of atorvastatin on
CRP levels achieved at 1 year, we fitted linear regression
models to the log-transformed CRP values 1 year post
randomisation and included treatment group and log baseline
CRP as explanatory variables; the percentage difference in
CRP due to treatment was obtained from the β-coefficient
for atorvastatin (by taking the exponential, subtracting 1 and
multiplying by 100). To estimate the absolute treatment dif-
ference we fitted similar models using median regression.
Two model adjustments were presented: model 1, for age
and sex; and model 2, additionally for race (white vs non-
white), smoking status (current vs none/past), systolic blood
pressure, BMI, HbA1c, change in LDL-cholesterol, and days
between randomisation and CRP measurement. Intention-to-
treat analysis was compared with on-treatment analysis to
check for bias due to participants not taking statins.
Pearson correlation coefficients were computed to test
whether CRP levels were correlated with LDL-cholesterol
levels using log-transformed CRP values, separately for base-
line, 1 year and changes over time, and to test correlations
with other cardiovascular risk factors.
To test the association between baseline CRP and incidence
of (major/any) CVD we used Cox proportional hazards
models. These models were adjusted for age, sex and treat-
ment allocation in model 1, and additionally for race, smoking
status, baseline systolic blood pressure, BMI, HbA1c and
LDL-cholesterol in model 2. We tested associations with in-
cident CVD for achieved 1 year CRP and changes in CRP by
modelling the time from 1 year CRP measurements to the first
subsequent CVD event. Those with CVD events within the
first year were excluded from analyses. Of 2,322 study partic-
ipants, ten had missing LDL-cholesterol at 1 year, one had an
implausible LDL-cholesterol measurement, one was lost to
follow-up and 52 had CVD within the first year, leaving
2,258 participants for analysis. Model 2 extended with all
confounders further dropped 35 participants from the analy-
ses, leaving 2,223 participants for analysis. CRP was also
examined as a continuous variable (per 1 SD increase in loge-
transformed CRP) and by tertiles or quartiles for non-linearity.
Similar multivariable Cox proportional hazards models were
used to examine associations between baseline, 1 year and
changes in LDL-cholesterol and incident (major/any) CVD.
To examine whether the effect of atorvastatin on major (or
any) CVD varied by strata of achieved 1 year levels of CRP
and LDL-cholesterol, and by combinations of achieved CRP
and LDL-cholesterol, we used Cox proportional hazards
models to estimate the HRs for CVD compared with placebo.
For comparability with guidelines [18, 19] and earlier
reports to define these strata, post-treatment CRP and
LDL-cholesterol were dichotomised at various cut-points in-
cluding post-treatment above and below median levels, and
above and below specific target levels as in JUPITER [6] or
ASCOT [11, 12]. Several adjustments were performed in model
0 for baseline CRP or LDL-cholesterol; in model 1 for age and
sex; and, inmodel 2, further adjustment for race, smoking status,
systolic blood pressure, BMI and HbA1c. We formally tested for
interactions between the effect of atorvastatin and CRP or LDL-
cholesterol by adding interaction terms (atorvastatin×CRP
above/below targets) to the Cox models.
Results
During 3.8 years of follow-up, 147 major CVD events and
244 any CVD events occurred in 2,322 participants with CRP
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data. Themean age of the participants was 61.6 years (SD 8.1)
and 69% were male. A comparison of the baseline character-
istics by treatment arm in those with CRP data (electronic
supplementary material [ESM] Table 1) showed that both
treatment arms were well balanced in terms of all characteris-
tics, except for slightly lower baseline CRP levels in the ator-
vastatin compared with the placebo arm. In both arms com-
bined, the median (interquartile range, IQR) baseline CRP
levels were 13.3 (5.8, 31.9) nmol/l [1.4 (0.6, 3.4) mg/l]. The
baseline median LDL-cholesterol concentration was 3.1 (2.6,
3.6) mmol/l [118.4 (99.8, 137.6) mg/dl]. Baseline CRP
showed expected correlations with baseline risk CVD factors
(ESM Table 2): for example, loge CRP was positively associ-
ated with BMI (Pearson correlation coefficient 0.24,
p<0.001).
Effects of atorvastatin on CRP The atorvastatin arm
showed a 9.8% reduction in CRP at 1 year (from baseline;
median within-person change; Table 1) compared with an
18.5% increase in the placebo group. The net effect of atorva-
statin on CRP levels was −32% (p<0.0001) compared with
placebo. By comparison, atorvastatin reduced LDL-cholesterol
levels by 42% (p<0.0001) from baseline to 1 year. Only four
people in the atorvastatin group and seven in the placebo group
were not on treatment 1 year after randomisation. Restricting
the analyses to those still on treatment gave similar results to
those produced in the intention-to-treat analysis.
Although there was a net treatment effect on CRP, baseline
CRP and changes from baseline were much more variable
than LDL-cholesterol. The median (IQR) within-person abso-
lute change in CRP on statin was −1.0 (−9.4, 6.9) nmol/l
[−0.11 (−0.99, 0.72) mg/l], with 45% of those on statin having
no fall in CRP (median [IQR] within-person per cent change
−9.8% [−56, +115]. By contrast, the LDL-cholesterol re-
sponse was much less variable, with a median (IQR) fall in
LDL-cholesterol in 96% of people on the statin of 41%
(−51%, −31%). Furthermore, the correlation coefficients be-
tween baseline log-transformed CRP and LDL-cholesterol
levels were low at 0.04 (p=0.03). Low, although statistically
significant, correlations were also found between on-treatment
CRP and LDL-cholesterol and change in log-transformed
CRP and LDL-cholesterol (0.14 [ p<0.0001] and 0.07
[p=0.001], respectively).
CRP, LDL-cholesterol and CVD We analysed the relation-
ship between CRP and CVD risk in all patients, using a linear
term for CRP (per 1 SD in loge CRP). No relationship was
seen for baseline, 1 year or change in CRP over time (HR ∼1
for major or any CVD). Stratified by treatment group, there
was a weak, non-significant association (HR 1.17 [95% CI
0.94, 1.45]) between baseline CRP (per 1 SD in loge CRP)
and incidence of any CVD event in the atorvastatin group
only, whereas in the placebo group the HR was 0.95 (95%
CI 0.80, 1.13) after adjustment for other covariates beyond
Table 1 Effect of atorvastatin
therapy on CRP concentrations in
2,322 patients with type 2
diabetes
Intention-to-treat analysis Placebo
(n=1,148)
Atorvastatin
(n=1,174)
CRP, nmol/l [mg/l]
Baseline, median (25th, 75th percentile) 14.5 (5.8, 33.8)
[1.5 (0.6, 3.6)]
12.6 (5.9, 29.4)
[1.3 (0.6, 3.1)]
12 months, median (25th, 75th percentile) 17.2 (8.0, 39.2)
[1.8 (0.8, 4.1)]
11.9 (5.1, 27.3)
[1.2 (0.5, 2.9)]
Change, % median (25th, 75th percentile) 18.5 (−41.4, 204.8) −9.8 (−56.5, 115.2)
Net treatment effect
ANCOVA using log-transformed CRP values, % difference in CRP compared with placebo (95% CI)
Model 1a −29.9 (−35.9, −23.3)*
Model 2b −32.0 (−40.4, −22.4)*
ANCOVA using median regression of untransformed CRP values, absolute difference in CRP compared with
placebo (95% CI)
Model 1a, nmol/l [mg/l] −4.9 (−6.1, −3.8)
[−0.5 (−0.6, −0.4)]*
Model 2b, nmol/l [mg/l] −4.4 (−6.4, −2.3)
[−0.5 (−0.7, −0.2)]*
aModel 1, age and sex
bModel 2, race, smoking status, systolic blood pressure, BMI, HbA1c, change in LDL-cholesterol, days between
randomisation and CRP measurement; this model is based on 2,311 participants with complete covariate data
*p<0.0001 vs placebo
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age and sex. In case there was a non-linear relationship we
also categorised baseline CRP levels into tertiles (Table 2): no
significant relationship between CRP and CVD risk adjusted
for treatment was found, except for the composite event of any
CVD (HRtop vs bottom tertile 1.35 [95% CI 0.98, 1.86]), and this
apparent effect was no longer significant after adjust-
ment for other covariates beyond age and sex. Baseline
LDL-cholesterol levels predicted major CVD independently
of age, sex, treatment, race, smoking status, systolic blood
pressure, BMI and HbA1c, with an HR of 1.21 (95% CI
1.02, 1.44) (Table 2). Similar associations were found with
any CVD, for baseline, 1 year LDL-cholesterol levels and
changes in LDL-cholesterol levels.
Effect of atorvastatin on CVD by achieved lowering of
CRP or LDL-cholesterol The median (IQR) achieved
LDL-cholesterol level was 3.12 (2.58, 3.64) mmol/l [121
(100, 141) mg/dl] in the placebo arm and 1.79 (1.41, 2.23)
mmol/l [60 (65, 86) mg/dl] in the atorvastatin arm. The medi-
an achieved CRP level was 17.2 (8.0, 39.1) nmol/l [1.81 (0.84,
4.12) mg/l] in the placebo arm and 11.8 (5.0, 27.2) nmol/l
[1.24 (0.53, 2.86) mg/l] in the atorvastatin arm. Compared
with the placebo group, the reduction in CVD with atorvastat-
in was not significantly different by categories of 1 year
LDL-cholesterol or CRP levels achieved at any binary cut-
point used (Table 3). The HRs of the effect of atorvastatin vs
placebo on CVD risk were 0.5–0.7, which is consistent with
the overall effect in the total trial population, including those
without CRP data [1]. There was no evidence of significant
interactions (all p≥0.9) between the overall efficacy of ator-
vastatin on major CVD events and achieved CRP above/
below targets or LDL-cholesterol above/below targets. These
results persisted after adjustment for age, sex, smoking status,
race, systolic blood pressure, BMI and HbA1c. Nor did we
find any significant differences in effects on incidence of
any CVD by category of achieved LDL-cholesterol or CRP.
Table 2 Event rates across tertiles of baseline CRP and LDL-cholesterol in the CARDS population
Event type by tertile or per unit SD Events/persons
(event rate/100 person-years)
Model 1a Model 2b
HR (95% CI) p value HR (95% CI) p valued
CRPc
Major cardiovascular event (n=147)
Tertile 1, <7.9 nmol/l 52/772 (1.72) 1 1
Tertile 2, 7.9–23.8 nmol/le 55/776 (1.89) 1.19 (0.82, 1.75) 1.11 (0.75, 1.63)
Tertile 3, ≥23.8 nmol/l 40/774 (1.38) 1.05 (0.69, 1.60) 0.755 0.88 (0.57, 1.35) 0.589
SD unit of log CRP 0.97 (0.82, 1.15) 0.730 0.89 (0.75, 1.06) 0.205
Any cardiovascular event (n=244)
Tertile 1, <7.9 nmol/l 76/772 (2.55) 1 1
Tertile 2, 7.9–23.8 nmol/le 87/776 (3.07) 1.27 (0.93, 1.73) 1.17 (0.86, 1.60)
Tertile 3, ≥23.8 nmol/l 81/774 (2.87) 1.35 (0.98, 1.86) 0.061 1.14 (0.82, 1.58) 0.439
SD unit of log CRP 1.10 (0.97,1.25) 0.151 1.02 (0.89, 1.17) 0.749
LDL-cholesterolc
Major cardiovascular event (n=147)
Tertile 1, <2.75 mmol/l 44/773 (1.49) 1 1
Tertile 2, 2.75–3.40 mmol/l 45/774 (1.54) 1.07 (0.71, 1.62) 1.03 (0.68, 1.56)
Tertile 3, ≥3.40 mmol/l 58/774 (1.97) 1.44 (0.97, 2.13) 0.066 1.44 (0.97, 2.14) 0.065
SD unit of LDL-cholesterol 1.21 (1.02, 1.43) 0.029 1.21 (1.02, 1.44) 0.027
Any cardiovascular event (n=244)
Tertile 1, <2.75 mmol/l 73/773 (2.53) 1 1
Tertile 2, 2.75–3.40 mmol/l 78/774 (2.73) 1.10 (0.80, 1.51) 1.06 (0.77, 1.46)
Tertile 3, ≥3.40 mmol/l 93/774 (3.22) 1.33 (0.98, 1.82) 0.064 1.35 (0.99, 1.84) 0.054
SD unit of LDL-cholesterol 1.15 (1.01, 1.31) 0.036 1.16 (1.02, 1.32) 0.026
aModel 1, age, sex and treatment allocation
bModel 2, model 1+race, smoking status, systolic blood pressure, BMI, HbA1c and LDL-cholesterol for association between CRP and (major/any) CVD
c n=2,322 for CRP analyses and n=2,321 for LDL-cholesterol analyses
d p values are from likelihood ratio tests
e 7.9–23.8 nmol/l=0.83–2.49 mg/l
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Effect of atorvastatin on CVD by combinations of
achieved CRP and LDL-cholesterol Using a number of
models, there was no clear evidence that the achievement of
target CRP levels after the LDL-cholesterol target was
achieved resulted in further reductions in risk (Table 4).
Among patients with achieved LDL-cholesterol <1.8 mmol/l,
atorvastatin reduced the risk of CVD events, irrespective of
whether achieved CRP was ≥9.5 nmol/l or <9.5 nmol/l
(1 mg/l). Similar HRs with overlapping CIs were found with
1 year achieved levels of LDL-cholesterol and CRP regardless
Table 3 Effect of atorvastatin on CVD events by level of CRP or LDL-cholesterol achieved at 1 year
CVD event (N=2,258) Events/persons
(event rate/100 person-years)
Model 0a, adjusted HR
(95% CI)
Model 1b, adjusted HR
(95% CI)
Model 2c, adjusted HR
(95% CI)
Major cardiovascular event (116 cases)
Placebo (74 cases) 74/1,115 (2.33) 1 1 1
Atorvastatin (42 cases)
LDL-c <2 mmol/l [77 mg/dl] 28/719 (1.32) 0.54 (0.35, 0.83) 0.58 (0.37, 0.89) 0.58 (0.37, 0.90)
LDL-c ≥2 mmol/l [77 mg/dl] 14/424 (1.18) 0.58 (0.33, 1.03) 0.51 (0.28, 0.92) 0.51 (0.28, 0.91)
CRP <19.0 nmol/l [2 mg/l] 30/752 (1.35) 0.55 (0.36, 0.83) 0.53 (0.35, 0.82) 0.55 (0.36, 0.84)
CRP ≥19.0 nmol/l [2 mg/l] 12/391 (1.12) 0.57 (0.31, 1.06) 0.59 (0.32, 1.09) 0.54 (0.29, 1.01)
CRP fell by year 1 22/624 (1.22) 0.53 (0.33, 0.85) 0.54 (0.33, 0.86) 0.54 (0.34, 0.88)
CRP did not fall 20/519 (1.34) 0.58 (0.35, 0.95) 0.56 (0.34, 0.93) 0.55 (0.33, 0.91)
LDL-c <1.8 mmol/l [70 mg/dl] 19/577 (1.10) 0.45 (0.27, 0.74) 0.48 (0.29, 0.80) 0.48 (0.29, 0.81)
LDL-c ≥1.8 mmol/l [70 mg/dl] 23/566 (1.46) 0.69 (0.43, 1.10) 0.63 (0.39, 1.03) 0.63 (0.39, 1.02)
CRP <9.5 nmol/l [1 mg/l] 20/500 (1.30) 0.50 (0.30, 0.82) 0.49 (0.30, 0.80) 0.51 (0.31, 0.84)
CRP ≥9.5 nmol/l [1 mg/l] 22/643 (1.24) 0.61 (0.38, 0.99) 0.62 (0.38, 1.00) 0.58 (0.36, 0.94)
% Change in LDL-c<mediand 21/588 (1.19) 0.50 (0.31, 0.81) 0.50 (0.30, 0.80) 0.50 (0.31, 0.82)
% Change in LDL-c≥median 21/555 (1.37) 0.62 (0.38, 1.01) 0.62 (0.38, 1.01) 0.61 (0.37, 1.00)
% Change in CRP<mediane 20/571 (1.20) 0.51 (0.31, 0.84) 0.52 (0.32, 0.85) 0.52 (0.32, 0.86)
% Change in CRP≥median 22/572 (1.35) 0.60 (0.37, 0.96) 0.58 (0.36, 0.94) 0.57 (0.35, 0.92)
Any cardiovascular event (190 cases)
Placebo (116 cases) 116/1,115 (3.73) 1 1
Atorvastatin (74 cases)
LDL-c <2 mmol/l [77 mg/dl] 44/719 (2.10) 0.55 (0.39, 0.78) 0.58 (0.41, 0.83) 0.59 (0.41, 0.84)
LDL-c ≥2 mmol/l [77 mg/dl] 30/424 (2.59) 0.76 (0.50, 1.14) 0.67 (0.44, 1.03) 0.67 (0.44, 1.02)
CRP <19.0 nmol/l [2 mg/l] 52/752 (2.37) 0.61 (0.44, 0.85) 0.62 (0.45, 0.86) 0.64 (0.46, 0.89)
CRP ≥19.0 nmol/l [2 mg/l] 22/391 (2.08) 0.62 (0.39, 0.99) 0.62 (0.39, 0.99) 0.58 (0.36, 0.93)
CRP fell by year 1 44/624 (2.49) 0.68 (0.48, 0.96) 0.67 (0.48, 0.96) 0.67 (0.47, 0.95)
CRP did not fall 30/519 (2.03) 0.54 (0.36, 0.82) 0.55 (0.37, 0.83) 0.56 (0.37, 0.84)
LDL-c <1.8 mmol/l [70 mg/dl] 31/577 (1.81) 0.47 (0.32, 0.70) 0.50 (0.33, 0.75) 0.51 (0.34, 0.77)
LDL-c ≥1.8 mmol/l [70 mg/dl] 43/566 (2.80) 0.80 (0.56, 1.14) 0.74 (0.51, 1.06) 0.73 (0.51, 1.06)
CRP <9.5 nmol/l [1 mg/l] 37/500 (2.46) 0.61 (0.42, 0.89) 0.62 (0.43, 0.90) 0.65 (0.45, 0.95)
CRP ≥9.5 nmol/l [1 mg/l] 37/643 (2.12) 0.62 (0.43, 0.90) 0.62 (0.43, 0.90) 0.59 (0.40, 0.86)
% Change in LDL-c<mediand 38/588 (2.19) 0.58 (0.40, 0.84) 0.57 (0.40, 0.83) 0.59 (0.41, 0.85)
% Change in LDL-c≥median 36/555 (2.38) 0.66 (0.45, 0.97) 0.67 (0.46, 0.97) 0.65 (0.45, 0.96)
% Change in CRP<mediane 42/571 (2.58) 0.69 (0.48, 0.98) 0.69 (0.48, 0.98) 0.68 (0.48, 0.97)
% Change in CRP≥median 32/572 (1.98) 0.54 (0.36, 0.80) 0.55 (0.37, 0.82) 0.53 (0.37, 0.83)
aModel 0, age and sex
bModel 1, model 0+baseline LDL-cholesterol or CRP
cModel 2, model 1+race, smoking status, systolic blood pressure, BMI and HbA1c
d Themedian (IQR) achieved LDL-cholesterol level was 3.12 (2.58, 3.64)mmol/l [121 (100, 141)mg/dl] in the placebo arm and 1.79 (1.41, 2.23) mmol/l
[60 (65, 86) mg/dl] in the atorvastatin arm
e The median (IQR) achieved CRP level was 17.2 (8.0, 39.1) nmol/l [1.81 (0.84, 4.12) mg/l] in the placebo arm and 11.8 (5.0, 27.2) nmol/l [1.24 (0.53,
2.86) mg/l] in the atorvastatin arm
LDL-c, LDL-cholesterol
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of cut-points used. In summary, with overlapping CIs between
all comparisons and non-significant p values for interaction (all
above 0.6), there was no difference in the effect of atorvastatin
vs placebo on CVD events in any of the combined groups of
achieved 1 year LDL-cholesterol or CRP targets.
Discussion
In this study we found that CRP was not an important predic-
tor of CVD in patients with type 2 diabetes. There was a net
lowering of CRP levels by atorvastatin 10 mg daily in this
primary prevention diabetic population, with 32% lower
CRP levels at 1 year. However, there was considerably greater
variability in CRP than in LDL-cholesterol response. The
magnitude of statin efficacy in the prevention of CVD did
not differ by achieved on-treatment CRP levels. Combining
LDL-cholesterol and CRP on-treatment categories demon-
strated similar reduced relative risks of CVD by atorvastatin
compared with placebo in all comparisons. Thus, CARDS
does not yield any evidence to support the use of CRP as an
indicator of efficacy of statin therapy on CVD risk in patients
with type 2 diabetes.
We did not find any consistent association between base-
line or post-treatment CRP levels and major (or any) CVD.
Several prospective cohort studies in patients with type 2 di-
abetes [20–23] have demonstrated elevated CVD risk with
higher CRP levels, with HRs ranging between 1.4 and 2.6.
In previous studies, higher CRP levels were indicated on a
continuous scale per SD log unit [23] or were divided into
categories greater than 3 mg/l [21, 22] or by quartiles [20].
In most of these studies, however, CRP levels were much
higher (ranging from 1.8 to 3 mg/l) than in our study popula-
tion (median 1.4 mg/l). Our study population of patients with
type 2 diabetes without prior CVD had intermediate CRP
values and were at modest risk of CVD events [24]. Our find-
ings are consistent with some studies that directly compared
patients with diabetes with those without and found that asso-
ciations between CRP and CVD were generally weaker and
not significant in patients with type 2 diabetes compared with
non-diabetic individuals [25–27]. Their explanation was that
other CVD risk factors typical for patients with type 2 diabetes,
such as high triacylglycerol levels, low HDL-cholesterol
levels, hypertension and hyperglycaemia, partially mask the
role of CRP as a risk factor for CVD, which could also
contribute to the lack of association with CVD in our study.
In contrast with the results for CRP, both baseline and
on-treatment LDL-cholesterol were clear predictors of CVD.
We did find a net lowering of CRP levels with atorvastatin
10 mg daily in patients with type 2 diabetes. Primary preven-
tion trials with various statins and varying study periods in
non-diabetic patients previously demonstrated that statin ther-
apy significantly decreased levels of CRP and showed signif-
icant net treatment effects compared with placebo, ranging
between −27% and −37%, which was comparable with our
treatment effect of −32% [6, 11, 13]. We also found a low
correlation between CRP change and LDL-cholesterol change
with statin. This low correlation has been asserted in previous
studies to be consistent with the pleiotropic effects of statins.
However, it may also simply reflect that CRP levels are much
more variable than LDL-cholesterol and that change in CRP
with statin is much more variable than change in LDL-
Table 4 Effect of atorvastatin on
CVD categorised by combined
1 year achievement of
LDL-cholesterol and CRP levels
CVD event (N=2,258) Events/persons Event rate
(per 100 person-years)
Adjusted
HRa (95% CI)
Major cardiovascular event
Placebo 74/1,115 2.33 1
Atorvastatin subgroups
LDL-c <1.8 mmol/l, CRP <19.0 nmol/l 14/400 1.14 0.44 (0.25, 0.78)
LDL-c <1.8 mmol/l, CRP ≥19.0 nmol/l 16/352 1.59 0.69 (0.40, 1.19)
LDL-c ≥1.8 mmol/l, CRP <19.0 nmol/l 5/177 0.98 0.47 (0.19, 1.16)
LDL-c ≥1.8 mmol/l, CRP ≥19.0 nmol/l 7/214 1.24 0.68 (0.31, 1.47)
Any cardiovascular event
Placebo 116/1,115 3.73 1
Atorvastatin subgroups
LDL-c <1.8 mmol/l, CRP <19.0 nmol/l 24/400 1.99 0.55 (0.35, 0.86)
LDL-c <1.8 mmol/l, CRP ≥19.0 nmol/l 28/352 2.84 0.73 (0.48, 1.12)
LDL-c ≥1.8 mmol/l, CRP <19.0 nmol/l 7/177 1.38 0.41 (0.19, 0.89)
LDL-c ≥1.8 mmol/l, CRP ≥19.0 nmol/l 15/214 2.72 0.69 (0.39, 1.23)
a Adjusted for age, sex, baseline LDL-cholesterol, baseline CRP, race, smoking status, systolic blood pressure,
BMI and HbA1c
LDL-c, LDL-cholesterol
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cholesterol. Consistent with this, we found a wide variability
in the change in CRP on statin, with almost half (45%) of
those on statin not having any fall in CRP and a narrow var-
iability in LDL-cholesterol, as almost all participants (96%)
had a fall in LDL-cholesterol by atorvastatin with a narrow
IQR in response. In order to demonstrate whether changes in
LDL-cholesterol or CRP associated with treatment relate to
the magnitude of the treatment effect of atorvastatin on CVD
there needs to be considerable variation among those assigned
to atorvastatin in the change observed in that biomarker. Thus,
the power to demonstrate variability in the HR for CVD with
atorvastatin is considerably less here for LDL-cholesterol
than for CRP. Despite this, we could not find any var-
iability in the CVD response by either achieved CRP or
LDL-cholesterol.
A meta-regression of 23 placebo-controlled trials previously
noted the lack of support for a pleiotropic effect and
demonstrated that at least 90% of the CRP reduction
detected with therapies to lower LDL-cholesterol can
be explained by reductions in LDL-cholesterol [28].
We found no clear evidence that the efficacy of atorvastatin
on CVD varied by achieved CRP level. This lack of associa-
tion has been reported previously in ASCOT [11, 12]. ASCOT
investigators demonstrated both in a nested case–control
design [11] and a more recent cohort design [12] that in
hypertensive patients neither baseline nor achieved CRP
levels with atorvastatin 10 mg/day predicted the efficacy
of statin treatment in preventing future CVD. On the contrary,
JUPITER [6] (n=15,548) demonstrated that rosuvastatin 20mg
daily reduced CVD by 55% during a median follow-up pe-
riod of 1.9 years in those who achieved on-treatment
LDL-cholesterol levels <1.8 mmol/l, by 62% in those
achieving CRP below 2 mg/l, and by 65% in those achieving
both LDL-cholesterol and CRP below target levels, supporting
the non-lipid benefits of statins. Patients with type 2 diabetes and
those with lower CRP levels were not investigated. However,
levels of CRP at baseline in CARDSwere less than half those in
JUPITER [6], with a baseline median CRP of 4.3 mg/l in the
placebo group, compared with 1.4 mg/l in our study, as
JUPITER selected men and women with a high baseline CRP
level (>2 mg/l). This may in part explain the discrepancy in
findings between our study and those of JUPITER.
Strengths of our study are the large number of patients with
type 2 diabetes and a relatively long follow-up time (almost
4 years), with no constraints on CRP levels at baseline. The
study findings can be generalised to a wider population of
patients with type 2 diabetes. Although the inclusion criteria
required that for individuals to be eligible for randomisation
one or more additional risk factors for CVD should be present,
we think that in fact most patients with type 2 diabetes prob-
ably have at least one risk factor anyway [1]. Limitations are
the relatively few CVD events due to early termination of
CARDS because of the emergence of clear evidence of
benefit. Therefore, major and any CVD (including peripheral
vascular disease) were included as study outcomes. Due to
limited events, subgroup analyses of the effect of statin therapy
on CVD events by combined achieved LDL-cholesterol and
CRP levels must be interpreted carefully.
In summary, we did not find any evidence to support the
idea that reduction of CVD by statins in patients with modest
CRP levels is mediated by lowering CRP. The use of CRP as
an indicator of the efficacy of statin therapy on CVD risk in
patients with type 2 diabetes is not supported by these data.
Two large placebo-controlled trials using targeted anti-
inflammatory drugs for secondary prevention of myocardial
infarction have been initiated, namely the Canakinumab Anti-
inflammatory Thrombosis Outcomes Study (CANTOS) and
the Cardiovascular Inflammation Reduction Trial (CIRT)
[29]. Fundamental evidence for the CVD benefits of reducing
inflammation must await these trials.
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